ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Recommendation of “Buy” from Analysts

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has been assigned a consensus recommendation of “Buy” from the eight brokerages that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $77.71.

ANIP has been the subject of several research reports. Piper Sandler initiated coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They set an “overweight” rating and a $68.00 price objective for the company. StockNews.com lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. HC Wainwright reaffirmed a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. Finally, Raymond James raised their target price on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 18th.

ANI Pharmaceuticals Trading Up 2.5 %

Shares of ANIP opened at $55.50 on Friday. The firm’s 50-day moving average is $57.57 and its two-hundred day moving average is $59.70. ANI Pharmaceuticals has a twelve month low of $52.50 and a twelve month high of $70.81. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The firm has a market capitalization of $1.17 billion, a P/E ratio of -100.91 and a beta of 0.73.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.09 by $0.25. The firm had revenue of $148.30 million for the quarter, compared to analyst estimates of $144.37 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. ANI Pharmaceuticals’s revenue was up 12.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.05 EPS. On average, research analysts predict that ANI Pharmaceuticals will post 3.87 earnings per share for the current fiscal year.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total transaction of $60,000.00. Following the transaction, the senior vice president now owns 49,059 shares of the company’s stock, valued at $2,943,540. The trade was a 2.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Nikhil Lalwani sold 33,481 shares of the company’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total value of $1,941,563.19. Following the completion of the transaction, the chief executive officer now directly owns 370,378 shares in the company, valued at approximately $21,478,220.22. This represents a 8.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 42,231 shares of company stock worth $2,434,286. 12.70% of the stock is owned by insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Innealta Capital LLC bought a new stake in ANI Pharmaceuticals in the second quarter valued at approximately $65,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of ANI Pharmaceuticals by 24.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock worth $177,000 after purchasing an additional 579 shares during the period. XTX Topco Ltd bought a new stake in shares of ANI Pharmaceuticals in the 2nd quarter valued at $207,000. HighTower Advisors LLC acquired a new stake in shares of ANI Pharmaceuticals during the third quarter worth $222,000. Finally, Profund Advisors LLC bought a new position in ANI Pharmaceuticals during the second quarter worth $225,000. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.